The present invention is targeted therapy characterized in that combines the properties of that, more particularly, to an optical and acoustic hypersensitivity agents, angiogenesis inhibitors, and tyrosine kinase inhibitors on the conjugate (conjugate) that the selectivity in tumor on the targeted therapy It relates to a conjugate in the tumor selectivity on. The conjugate may be characterized in that it comprises a light and sound hypersensitivity agents, angiogenesis inhibitors, and tyrosine kinase inhibitors, the target ligand and the linker. The conjugate and its application with a selectivity to tumor according to the present inventors targeted therapy is the present invention that are relevant to a specific than in photodynamic therapeutic and pharmacological has the properties of blood vessel formation and tyrosine kinase inhibitors, cancer and a drug for other diseases may be used in the manufacture. In particular the invention is related to the production method of the compound based on the compound based on curcuminoids and porphyrins for drug conjugate, cancer and other disease states and treatment based on curcuminoids porphyrin conjugates. Invention may also related to the therapy based on the composition, it may be that it provides an anti-cancer, anti-angiogenic, inhibitory effect of the proposed drug, toxicity in the excellent solubility, therapeutic bioavailability, stability, cancer and other diseases in aqueous solution It has an advantageous effect that a lack. Furthermore, the present invention can be used for oral, nasal and rectal administration for the treatment of cancer and other disease states.본 발명은 표적 치료에 관한 종양에 선택성이 있는 콘쥬게이트(conjugate)에 관한 것으로, 보다 상세하게는 광 및 음향 과민제, 혈관형성 억제제 및 타이로신 카이나제 억제제의 성질을 결합한 것을 특징으로 하는 표적 치료에 관한 종양에 선택성이 있는 콘쥬게이트에 관한 것이다. 상기 콘쥬게이트는 광 및 음향 과민제, 혈관형성 억제제 및 타이로신 카이나제 억제제, 표적 리간드 및 링커를 포함하는 것을 특징으로 할 수 있다.본 발명인표적 치료에 관한 종양에 선택성이 있는 콘쥬게이트 및 이의 응용은 광역학치료제에 보다 특이적으로 그리고 약리학적으로 관련이 있는 본 발명은 혈관형성과 타이로신 카이나제 억제제의 성질을 가
